This study looks at how well a drug called icotrokinra works for people with moderately to severely active Crohn's disease. Crohn's disease (CD) is a condition where the intestines get very inflamed, causing pain and other issues. The study checks both the effectiveness and safety of icotrokinra.

To join the study, participants need to have had CD for at least 12 weeks. They must show signs of active disease through tests and have tried other treatments without success. Participants should not have certain complications that might need surgery or affect the study's tests.

• The study requires participants to take part in regular check-ups and tests.
• There are specific criteria to join, including past treatments and current health status.
• Participants with certain complications or surgeries may not be eligible.